Developing nanomedicines that avoid fast blood clearance while retaining targeting specificity in vivo is inherently challenging. Leveraging the individual biomolecular corona, optimizing the nature of targeting ligands and exploring alternative stealth formulations might be the key to engineering tailored nanomedicine approaches.
